Abstract library

1836 results for "gastric neuroendocrine neoplasms type 1".
#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero
#407 Co-existing Type-1 Gastric Neuroendocrine Tumors (NETs) and Adenocarcinoma in Autoimmune Associated Atrophic Gastritis
Introduction: Autoimmune gastritis (AIG) causes oxyntic gland atrophy. This condition is often associated with Type-1 gastric NET secondary to achlorhydria and hypergastrinemia. Similar to atrophic gastritis in non-autoimmune conditions, AIG is associated with intestinal metaplasia that could progress to glandular dysplasia.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Laura Tang
Authors: Tang L
#763 Endoscopic Therapy with Argon Plasma Coagulation for Multiple Type 1 Gastric Carcinoid Tumors
Introduction: Data regarding Type I gastric carcinoids and their evolution in prospective series are scarce, thus treatment and follow-up are not codified.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Rodrigo Castano
#1070 Subtype Classification and Clinicopathological Characteristics of 78 Cases with Gastric Neuroendocrine Neoplasms
Introduction: Gastric NENs are a group of neoplasms with diverse clinicopathological features.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Zhang C, Tan H Y, Liu J X, Luo J, ...
#1287 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: Experiences in 116 Chinese Patients
Introduction: Gastric NEN are a heterogeneous group of tumors.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Zhang P, Zhang C, Luo J, Liu J X, ...
Keywords: gastric nen, type 1
#1307 Expression of m-TOR Pathway Components in Gastric Neuroendocrine Neoplasms: A Pilot Study
Introduction: The mammalian target of rapamycin (mTOR) signaling pathway plays a key role in the regulation of cell proliferation, protein synthesis and neuroendocrine tumor growth.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Vera Delektorskaya
#1393 Clinical Epidemiology Study of Gastric Neuroendocrine Neoplasms in China
Introduction: Tumor grade is a major indicator of prognosis for neuroendocrine neoplasms.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Zhang Yu-Qing
Authors: Zhang Y, Fan J H, Chen Y, Shi S S, ...
#1512 Type I Gastric Neuroendocrine Tumors Diagnostics: 16 Years of Experience
Introduction: In our institution from 1998 to 2014 we have identified 72 patients with type I gastric neuroendocrine tumors (NET).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Sergey Pirogov
#1584 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: An Analysis of 241 Cases
Introduction: Definition of type 3 gastric NEN in 2012 and 2016 ENETS guidelines is not clear, so Four-type classification has been proposed.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Prof. Huang-Ying Tan
Authors: Tan H Y, Dou D, Zhang P, Zhang C, ...
Keywords: gastric nen, subtype
#1593 Role of SSA in the Management of Multiple Type 1 Gastric Neuroendocrine Neoplasms
Introduction: Type 1 g-NENs associated with autoimmune chronic atrophic gastritis have high risk of recurrence but rare metastasis. Most type 1 patients are managed by endoscopic approach. The clinical benefit of somatostatin analogues (SSA) for type 1 g-NENs is controversial.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Prof. Huang-Ying Tan
Authors: Li Y L, Dou D, Tan H Y, ...
Keywords: SSA, gastric nen, type 1